Abstract: The short packet transmission (SPT) has gained much attention in recent years. In SPT, the most significant characteristic is that the finite blocklength code (FBC) is adopted. With FBC, the ...

The items were taken in the late 19th century from what was then called the Dutch East Indies. Indonesia had been trying to get them back for decades. By Nina Siegal Reporting from Amsterdam The ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Investing.com -- Recursion Pharmaceuticals (NASDAQ:RXRX) stock rose 7% Monday following positive Phase 2 trial results for its experimental drug REC-4881 in familial adenomatous polyposis (FAP), a ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

While we may have gotten away with high-volume, high-intensity training and minimal recovery in our twenties, we lose some of that flexibility as time goes on. Gone are the days when we could down a ...

Kristen Stewart is weighing in on the Method acting debate. “The Chronology of Water” director recently told the New York Times that acting is by nature “quite embarrassing and unmasculine,” and that ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

Recursion Pharmaceuticals (RXRX) is drawing renewed attention after the appointment of Najat Khan as CEO and news of a narrowing net loss, both viewed as signals of improving execution. Investors also ...

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...